Hemispherx Biopharma To Present Clinical Interpretations On CFS Treatment At The 11th Biennial International Research And Clinical Conference

Published: Mar 19, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA, March 19, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) will participate in the 11th Biennial International Research and Clinical Conference to be held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is "Differential Exercise Responses to Rintatolimod [Ampligen®] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.

Help employers find you! Check out all the jobs and post your resume.

Back to news